Life after abciximab; what's next for intracoronary thrombus?

J Thromb Thrombolysis. 2020 Jan;49(1):138-140. doi: 10.1007/s11239-019-01977-9.

Abstract

A case is described in which the short-acting glycoprotein IIb/IIIa receptor antagonist tirofiban was used in combination with heparin, aspirin and prasugrel to successfully treat extensive intracoronary thrombus in a delayed presentation STEMI, illustrating the utility of this approach.

Keywords: Abciximab; Coronary; Stent; Thrombus; Tirofiban.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Abciximab*
  • Aged
  • Aspirin / administration & dosage*
  • Coronary Thrombosis / complications
  • Coronary Thrombosis / drug therapy*
  • Heparin / administration & dosage*
  • Humans
  • Male
  • Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors
  • Prasugrel Hydrochloride / administration & dosage*
  • ST Elevation Myocardial Infarction / complications
  • ST Elevation Myocardial Infarction / drug therapy*
  • Tirofiban / administration & dosage*

Substances

  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Heparin
  • Prasugrel Hydrochloride
  • Tirofiban
  • Aspirin
  • Abciximab